MICHAEL JAMES OVERMAN to Angiogenesis Inhibitors
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Angiogenesis Inhibitors.
Connection Strength
0.104
-
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
Score: 0.104
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.